This company has been acquired
SPPI Stock Overview
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Spectrum Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$1.57 |
| 52 Week Low | US$0.32 |
| Beta | 2.14 |
| 1 Month Change | 4.54% |
| 3 Month Change | -1.90% |
| 1 Year Change | 17.05% |
| 3 Year Change | -71.39% |
| 5 Year Change | -95.10% |
| Change since IPO | -99.25% |
Recent News & Updates
Recent updates
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
May 14
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates
May 12Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC
Sep 20Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?
Sep 16Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection
Sep 09Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'
Aug 21Spectrum Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Jun 04Spectrum Pharmaceuticals: Some Last Words
Feb 25Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Oct 05Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
Aug 12Spectrum's Big Approval: Any Day Now
Jul 29Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
May 31We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
Feb 12Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like
Dec 21Shareholder Returns
| SPPI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.3% | 5.1% | -1.1% |
| 1Y | 17.0% | -14.9% | 9.1% |
Return vs Industry: SPPI exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: SPPI exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| SPPI volatility | |
|---|---|
| SPPI Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SPPI's share price has been volatile over the past 3 months.
Volatility Over Time: SPPI's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 86 | Tom Riga | www.sppirx.com |
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations.
Spectrum Pharmaceuticals, Inc. Fundamentals Summary
| SPPI fundamental statistics | |
|---|---|
| Market cap | US$209.89m |
| Earnings (TTM) | -US$67.71m |
| Revenue (TTM) | US$25.73m |
Is SPPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPPI income statement (TTM) | |
|---|---|
| Revenue | US$25.73m |
| Cost of Revenue | US$2.86m |
| Gross Profit | US$22.87m |
| Other Expenses | US$90.58m |
| Earnings | -US$67.71m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 88.90% |
| Net Profit Margin | -263.16% |
| Debt/Equity Ratio | 107.6% |
How did SPPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/02 05:47 |
| End of Day Share Price | 2023/07/31 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spectrum Pharmaceuticals, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Auriga USA LLC |
| David Buck | B. Riley Securities, Inc. |
| Alethia Young | Cantor Fitzgerald & Co. |